Drug Trial Radar · NCT06947980
Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jun 19, 2025
Primary completion
Jul 18, 2026
Study completion Nov 7, 2026
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
Placebo ComparatorDrug
Placebo subcutaneous injection
CM512Biological
CM512 subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from Baseline in Eczema Area and Severity Index (EASI) at Week 24Time frame: Baseline, Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.